Stock Analysis of Molecular Partners AG ADR (MOLN) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code MOLN
Close 3.60
Change -0.470 / 11.55 %
Volume 282.00
Vol Change -685.00 / 70.84 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Poor Growth Stock
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Molecular Partners AG ADR
PE (TTM)

-2.02

Very Poor
Price / Book

0.779

Very Good
Price / Sales

17.58

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

118328 K

Enterprise Value

-67352.96 K

ROA (TTM)

-34.03

Very Poor
ROE (TTM)

-38.55

Very Poor
Net Margin (TTM)

-870.22

Very Poor
Revenue

95.41 %

8699.00 K
Net Profit

150.60 %

-59634.00 K
Debt to Equity

0.0068

Excellent
Altman Z Score

2.01

Indecisive
Quick Ratio

0

Poor
Cash Ratio

12.96

Excellent


Highs/Lows of Molecular Partners AG ADR
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week3.8 5.26 % 0.513 % 4.22993.629-May-2431-May-24
Two Week3.78 4.76 % 0.486 % 4.22993.5829-May-2421-May-24
One Month3.781 4.79 % 4.80 % 4.493.5309-May-2415-May-24
Three Month4.3 16.28 % 3.56 % 4.93.3212-Apr-2419-Apr-24
Six Months4.2 14.29 % 15.54 % 5.083.3203-Jan-2419-Apr-24
One year6.42 43.93 % 26.26 % 7.323.3205-Jun-2319-Apr-24
Two year7.6 52.63 % 27.72 % 7.363.3223-Jan-2319-Apr-24
Five year15.58 76.89 % 91.77 % 7.360.023-Jan-2316-May-24


Technical View of Molecular Partners AG ADR
RSI

44.45

Neutral
MACD

0.0053

Bullish
ADX

18.64

Bullish
Super Trend

4.28

Mild Bearish
Williams %R

-90.00

Mild Bullish
CCI

-124.59

Strong Bearish


EMA 5

3.85

Strong Bearish
EMA 15

3.82

Strong Bearish
EMA 50

3.90

Neutral
EMA 100

4.09

Neutral
SMA 100

4.16

Neutral
SMA 200

4.46

Strong Bearish
SMA 5 / 20

3.90 / 3.78

Bullish
SMA 15 / 50

3.80 / 3.87

Mild Bearish
SMA 50 / 200

3.87 / 4.46

Strong Bearish




Charts of Molecular Partners AG ADR


Returns of Molecular Partners AG ADR with Peers
Period / StockMOLNFGENACETJUPW
1 Week-5.26%-7.69%-2.68%59.21%
1 Mth-4.79%7.14%-2.68%138.82%
3 Mth-16.28%-29.82%-38.30%215.65%
6mth-14.29%117.23%22.88%819.45%
1 Year-43.93%-93.04%-73.54%255.88%
2 Year-52.63%-87.80%-87.73%150.34%
5 Years-76.89%-96.69%-97.13%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Molecular Partners AG ADR with Peers
Ratio / StockMOLNFGENACETJUPW
PE-2.02-0.491-111.82-5.03
P/B0.779-1.0669.2316.78
ROA-34.03-52.02-53.10-181.90
ROE-38.550-117.73-333.85
Debt To Equity0.0068-0.5300.01890.603
Revenue8699.00 K
95.41 % 		154981 K
10.12 % 		0
100.00 % 		6196.74 K
115.44 %
Net Income-59634.00 K
150.60 % 		-294175.00 K
0.177 % 		-142658.00 K
112.83 % 		-15223.03 K
45.83 %


Technicals of Molecular Partners AG ADR with Peers
Technical / StockMOLNFGENACETJUPW-
ADX18.6418.4616.5149.53
CMF-0.483-0.434-0.3820.348
MFI67.9968.0756.7774.00
RSI44.4546.3340.3675.63
MACD Abv SignalTrueTrueTrueTrue
Price Above 50 MAFalseFalseFalseTrue-
Price Above 200 MAFalseTrueFalseTrue-


About : Molecular Partners AG ADR

Address : Wagistrasse 14, Schlieren, Switzerland, 8952
Tel : 41 44 755 77 00
URL : https://www.molecularpartners.com
Code : MOLN, ISIN : US60853G1067, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 16_Jun_2021
Employee Count : 167

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.


Note : All Data Generated at the End of Trading Hours (EOD Data)